CeNeS Pharmaceuticals plc

4 Kommentare / 0 neu
18.06.2007 10:16
#1
Bild des Benutzers jfk
jfk
Offline
Kommentare: 219
CeNeS Pharmaceuticals plc

CeNeS Pharmaceuticals plc

Der britische Biotechkonzern hat weiteres Datenmaterial zum Schmerzmittel M6G aus der klinischen Endphase III vorgelegt. M6G soll gegen postoperative Schmerzen zum Einsatz kommen. CeNeS verspricht sich von der Substanz dieselbe Wirksamkeit wie bei der herkömmlichen Behandlung mit Morphin, aber mit weitaus weniger Nebenwirkungen wie Übelkeit oder Erbrechen. Mit dem günstigen Nebenwirkungsprofil will CeNeS weiter punkten. Aus den neuen Daten geht hervor, dass bei M6G die Phase der Sedierung, in welcher der menschliche Organismus von Beruhigungsmitteln beeinträchtigt wird, innerhalb der ersten vier Stunden nach der Operation um 15% kürzer ausfiel als bei Morphin. Darüber hinaus wurden Häufigkeit und Schwere von postoperativer Übelkeit bei weiblichen Patienten um 27% weniger beobachtet als im Morphin- Arm der Phase-III-Studie

Könnte vielleicht interessant sein, kennt jemand diese Firma ? Any comments?

Danke für alle feedbacks

Aufklappen
20.06.2007 08:46
Bild des Benutzers jfk
jfk
Offline
Kommentare: 219
Wieder positive news heute morgen

CeNeS Pharmaceuticals plc

("CeNeS" or "the Company")

Pipeline update - CNS 7056

Cambridge, UK, 20th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the

Cambridge based biopharmaceutical company today announces new data on its

short-acting sedative, CNS 7056. These preclinical data show that CNS 7056

induces deep sedation, has a rapid onset of action and rapid offset of action

with predictable effects over a wide range of doses. On the basis of this

successful outcome, the compound will be developed for the indications of

induction and maintenance of anaesthesia in addition to sedation for day-case

procedures. CeNeS also announces that the first full academic paper on CNS 7056

will be published in the July issue of the leading journal 'Anesthesiology'. The

paper is one of a small number highlighted in the introductory section of this

issue.

Additional indications

Following the successful completion of studies at the University of Adelaide and

under a material transfer agreement with an International Pharmaceutical

company, CeNeS will develop CNS 7056 for the induction and maintenance of

anaesthesia in addition to the existing development for sedation during day-case

procedures. These latest pre-clinical studies show that CNS 7056 has the

desirable features for an anaesthetic drug of inducing deep sedation rapidly and

controllably, with predictable effects over a wide range of doses and a rapid

recovery.

Academic publication

CeNeS is pleased to note that the first full academic paper on CNS 7056 will be

published in the July issue of the leading international Journal

'Anesthesiology' and has been selected as a featured article for the section

'this month in Anesthesiology'.

Neil Clark, Chief Executive of CeNeS commented: "CNS 7056 shows an excellent

profile in preclinical studies. Development for the additional indications of

the induction and maintenance of anaesthesia means that the market potential is

significantly larger. We believe that the peak sales opportunity for this

compound is now doubled to £400m. We are looking forward to filing an IND for

this compound in the next few months and commencing Phase I clinical trials.

"CNS 7056 exemplifies CeNeS' strategy of focussing on low-risk programmes that

provide early and simple proof of concept in clinical trials. Indeed, an

important feature of this development programme is that we will be able to

generate proof of concept data on sedation/anaesthesia in Phase I volunteer

studies rather than having to wait for Phase II patient studies as is the case

for most drug development programmes."

Hat sich bis heute niemand mit diesem Titel befasst? Bin gespannt was ihr dazu zu sagen habt! Guten und erfolgreichen Start

19.06.2007 16:49
Bild des Benutzers jfk
jfk
Offline
Kommentare: 219
heute schon bereits +26%

:shock: :shock:

19.06.2007 08:39
Bild des Benutzers jfk
jfk
Offline
Kommentare: 219
CeNeS Pharmaceuticals plc

Hier noch mehr News

CENES PHARMACEUTICALS PLC ("the Company") HOLDING IN COMPANY The Company was informed on 14 June 2007 that as at the close of business on 8 June 2007 The Goldman Sachs Group, Inc. ("GS Inc.") had an interest, in 29,486,760 ordinary shares of 1p each in the capital of the Company. This interest arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. This shareholding represents 6.09 per cent. of the issued share capital of the Company. The threshhold crossed is from below 3% to above 6%.